A Six Month, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group Study to Estimate the Pharmacodynamic Response of Two Risedronate Regimens Compared With 5mg Daily : 150mg Monthly Dose for Six Months and 15mg Daily for Thirty Days Followed by 150mg Monthly Dose for 5 Months in Postmenopausal Women With Low Bone Density

Trial Profile

A Six Month, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group Study to Estimate the Pharmacodynamic Response of Two Risedronate Regimens Compared With 5mg Daily : 150mg Monthly Dose for Six Months and 15mg Daily for Thirty Days Followed by 150mg Monthly Dose for 5 Months in Postmenopausal Women With Low Bone Density

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Sep 2006

At a glance

  • Drugs Risedronic acid (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Pharmacodynamics
  • Sponsors Sanofi
  • Most Recent Events

    • 13 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top